<DOC>
	<DOCNO>NCT01544361</DOCNO>
	<brief_summary>This Phase 1 study evaluate safety tolerability single ascend intravenous dos MEDI7814 healthy adult subject .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Safety MEDI7814 Adult Volunteers</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , placebo-controlled study evaluate safety tolerability single ascend intravenous dos MEDI7814 healthy adult male subject female subject non-childbearing potential .</detailed_description>
	<criteria>Aged 18 year include 49 year time first dose investigational product Healthy medical history , physical examination , laboratory study Body weight 50125 kilogram ( kg ) ; body mass index 19.032.0 kilogram per square meter ( kg/m^2 ) ( inclusive ) Females must nonchildbearing potential . Exclusion criterion : Any acute illness within 30 day screen Concurrent enrollment another clinical trial The subject positive drug/alcohol screen screen Day 1 Pregnancy Current cigarette smoker History cancer nonmelanoma skin cancer situ carcinoma cervix treat apparent success Use immunosuppressive medication Subjects unresolved infection Neisseria species Subjects spleen remove reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>MEDI7814</keyword>
	<keyword>FTiH</keyword>
</DOC>